Tags

Type your tag names separated by a space and hit enter

Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 01; 35(4):1112-6.PN

Abstract

Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia.

Authors+Show Affiliations

NHS Health Trust n. 10 Veneto Orientale, Unit of Psychiatry of Portogruaro, Via Forlanini 2, 30026 Portogruaro, Venezia, Italy. Alessandro.DeRisio@ulss10.veneto.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21447367

Citation

De Risio, Alessandro, et al. "Add-on of Aripiprazole Improves Outcome in Clozapine-resistant Schizophrenia." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 35, no. 4, 2011, pp. 1112-6.
De Risio A, Pancheri A, Simonetti G, et al. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1112-6.
De Risio, A., Pancheri, A., Simonetti, G., Giannarelli, D., Stefanutto, L., & Gentile, B. (2011). Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry, 35(4), 1112-6. https://doi.org/10.1016/j.pnpbp.2011.03.011
De Risio A, et al. Add-on of Aripiprazole Improves Outcome in Clozapine-resistant Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1112-6. PubMed PMID: 21447367.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. AU - De Risio,Alessandro, AU - Pancheri,Angelo, AU - Simonetti,Giovanna, AU - Giannarelli,Diana, AU - Stefanutto,Luciana, AU - Gentile,Bruno, Y1 - 2011/04/05/ PY - 2010/11/26/received PY - 2011/03/04/revised PY - 2011/03/21/accepted PY - 2011/3/31/entrez PY - 2011/3/31/pubmed PY - 2011/9/14/medline SP - 1112 EP - 6 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog Neuropsychopharmacol Biol Psychiatry VL - 35 IS - 4 N2 - Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/21447367/Add_on_of_aripiprazole_improves_outcome_in_clozapine_resistant_schizophrenia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(11)00096-0 DB - PRIME DP - Unbound Medicine ER -